Related references
Note: Only part of the references are listed.NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people
J. F. Mayberry et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti-Tumor Necrosis Factor-α Agents
Christine Kestens et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Biosimilars in IBD: hope or expectation?
Krisztina B. Gecse et al.
GUT (2013)
ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)
Silvio Danese et al.
JOURNAL OF CROHNS & COLITIS (2013)
Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience
N. C. Suares et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients
E. Bultman et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (COMPAIRS)
Daniel A. Sussman et al.
INFLAMMATORY BOWEL DISEASES (2012)
Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience
Michael B. Sprakes et al.
JOURNAL OF CROHNS & COLITIS (2012)
Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Khurram J. Khan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience
Michael B. Sprakes et al.
JOURNAL OF CROHNS & COLITIS (2011)
Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience
M. B. Sprakes et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States
Michael D. Kappelman et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted county, Minnesota, 1940-2000
Conor G. Loftus et al.
INFLAMMATORY BOWEL DISEASES (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2005)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease
BG Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
